



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Szelenyi et al.

Examiner: Brian Kwong

Serial No.: 10/727,658

Art Unit: 1614

Filed: December 5, 2003

Title: COMBINATIONS OF POTASSIUM CHANNEL OPENERS AND SODIUM CHANNEL INHIBITORS OR SODIUM CHANNEL-INFLUENCING ACTIVE COMPOUNDS FOR TREATING PAINS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the duty of disclosure under 37 CFR §1.56 and pursuant to 37 CFR §§1.97-1.98, Applicant submits herewith an Information Disclosure Citation List, and a copy of each document listed therein.

The present Information Disclosure Statement is being filed after the mailing date of a first Office Action on the merits and thus a fee of \$180 is due pursuant to 37 C.F.R. §1.17(p). The Commissioner is hereby authorized to charge the fee, and to charge any deficiency or to credit any overpayment, to the undersigned attorney's Deposit Account No. 02-4270, with reference to attorney's docket No. 6319-1815. **A duplicate of this sheet is attached.**

The enclosed documents were either cited in the International Search Report ("the ISR") dated March 4, 2005 for a counterpart PCT application or is a U.S. patent document that is a counterpart to a non-English foreign patent document cited in the ISR. A copy of the ISR is enclosed.

Four of the foreign patent documents cited in the ISR are not in English. One of them, WO 01/22953, corresponds to U.S. Pat. 6,117, 900 to Rundfeldt et al. which is already of record. Of the remaining three, U.S. Patents 6,500,455 to Frantsits, 4,778,799 to Tibes et al., and

4,668,684 to Tibes et al, copies of which are enclosed, correspond to WO 00/59508, EP 189,788, and DE 3604575, respectively, and are submitted in lieu of translations.

L. Beck and M. Beck, *Der Gynaekologe*, 35:490-494 (2002) deals with the causes, diagnosis and treatment of "Kreuzschmerzen" (lumbago, lower back pain) in the practice of gynecology. The relevant portion is the paragraph entitled "Medikamente" on page 494, which translates as follows:

Medication: Initially, myotonolytics (muscle relaxants such as Predinol™ and Myoson™) as well as non-opioid analgesics are recommended for short term application. When inflammation is involved, the use of non-steroidal anti-inflammatory agents is indicated. Opioids should be limited to cases of chronic pain. With persistent pain, newer medicines such as flupirtine (Katadolon™) and tolperisone (Mydocalm™) are given.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant reserves the right to dispute any of the listed documents as prior art during examination. Furthermore, Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application. The submission of this Information Disclosure Statement is not to be construed as a representation that a search has been made or that no other material information may exist.

The Examiner is requested to consider the enclosed documents, and indicate his or her consideration of the documents by initialing the enclosed Citation List adjacent the citation of each document and returning a copy of the initialed list to the undersigned.

Respectfully submitted,

Date: March 15, 2007

By: Madelene Beck

Attorney Reg. No. 36, 437
Thelen Reid Brown Raysman & Steiner LLP
900 Third Avenue
New York, NY 10022
Telephone: (212) 895-2000
Facsimile: (212) 895-2900



PTO/SB/08A (09-06)

Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Shee

1

of 2

Complete if Known	
Application Number	10/727,658
Filing Date	December 5, 2003
First Named Inventor	Szelenyi, Istvan
Art Unit	1614
Examiner Name	Brian Kwong
Attorney Docket Number	6319-1815

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS


Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
		EP 189,788 A1	08-06-1986	Tibes et al.		
		JP 2000-143510A(abstract)	05-23-2000	Eiichiro		✓
		WO 00/59487 A2	10-12-2000	Stoll		
		DE 3604575 A1	08-28-1986	Tibes et al.		
		WO 01/22953 A2	04-05-2001	Rundfeldt et al.		
		WO 01/01970 A2	01-11-2001	Burbridge et al.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ²Applicant's unique citation designation number (optional). ³See Kinds Code of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ⁴Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁷Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08A (09-06)

Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

2

of 2

Complete if Known	
Application Number	10/727,658
Filing Date	December 5, 2003
First Named Inventor	Szelenyi, Istvan
Art Unit	1614
Examiner Name	Brian Kwong
Attorney Docket Number	6319-1815

U. S. PATENT DOCUMENTS


FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Sample for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

1

Complete if Known	
Application Number	10/727,658
Filing Date	December 5, 2003
First Named Inventor	Szelenyi, Istvan
Art Unit	1614
Examiner Name	Brian Kwong
Attorney Docket Number	6319-1815

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		KUO et al., Inhibition of Na ⁺ Current by Diphenhydramine and Other Diphenyl Compounds..., Molecular Pharmacology, 2000, 57(1):135-143	
		BECK et al., Kreuzschmerzen in der Gynaekologischen Praxis, Gynaekologe, Springer Verlag, Berlin Germany, 2002, 35(5):490-494.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.